The Tissue Engineering-based Regeneration Products Market is expected to grow at a 33.0 % CAGR during the forecast period for 2023-2031.
Integrating scaffolds, cells, and biologically active chemicals to create functioning tissues is referred to as tissue engineering. Tissue engineering emerged from the field of biomaterials development and referred to the practice. Tissue engineering aims to put together functional constructions to repair, maintain, or otherwise improve entire organs or damaged tissues. It is a large field that includes tissue engineering but also incorporates research on self-healing, when the body uses its systems, sometimes with the help of foreign biological material, to recreate cells and rebuild tissues and organs. Regenerative medicine is one of the more recent developments in the field of medicine. Many complex and more sophisticated tissue reconstructions have been successfully performed thanks to a novel technology. This indicates that more complex tissue engineering treatments may be conceivable in the near future. The market for tissue engineering will likely experience significant growth in the near future as a result of the rapid pace of innovation that is currently taking place in this sector, as well as the recent shift in consumer preference away from conventional transplant procedures and toward regeneration products that are based on tissue engineering.
Developments in stem cell technology and tissue engineering, an increase in the number of clinical studies for regenerative medicine and tissue engineering, and rising financing for tissue engineering research are all factors that are propelling the industry forward. Chronic diseases, including CVD, cancer, diabetes, ulcers, and genetic disorders like cystic fibrosis, have grown substantially in recent decades. Diabetes and obesity can increase the prevalence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, requiring costly therapies, which will turn into high demand for engineered regenerative products, pushing the market upside.
While some Tissue Engineering-based Regeneration Products show promise as an alternative to organ donation, they are not yet generally used due to their prohibitively high prices and the difficulties in obtaining reimbursements and insurance coverage. An inability to educate patients is another potential growth-limiting factor in the years ahead. Scaffolds have issues that include infections, mechanical failure, and immunogenic reactions to implanted materials. The expansion of the market will be stunted as a result.
Market Segmentation
The Tissue Engineering-based Regeneration Products Market is categorized into four segments Type of Grafts, area of application, type of material scaffold and type of end-user. By type of graft, it is segmented into allografts, autografts and xenografts. Whereas area of application includes bone healing, burn Healing, Surgical Healing, Wound Healing, and Others. In the case of a type of material scaffold, the segment contains Bone Tissue, Collagen-based Tissue, Human Placental Tissue, Other Animal Based Tissue, Other Human Tissue, Stem Cells and Others Tissues. In the end, the fourth category is end-user, which consists of Ambulatory Surgical Centers, Hospitals and Specialty Clinics.
By the region, North America will lead the Tissue Engineering-based Regeneration Products Market in the forecasting period 2022-2030 as the funding and government investment are increasing continuously.
Competitive Landscape
Some major key players in the Tissue Engineering-based Regeneration Products Market:
- AlloSource
- BioTissue
- Integra Lifesciences Corporation
- MiMedx
- Organogenesis, Inc.
- Smith +Nephew
- Tissue Regenix
- VIVEX Biologics
- Alliqua BioMedical, Inc.
- MISONIX, Inc.
- Arthrex, Inc.
- Braun Melsungen AG
- BARD, A Becton, Dickinson Company
- ConMed Corporation
- Globus Medical, Inc.
- Lattice Biologics Ltd.
- Osiris Therapeutics, Inc.
- Straumann
- Xtant Medical
- Zimmer Biomet Holdings, Inc.
Tissue Engineering-based Regeneration Products Market Report Scope
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 33.0 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Type of Graft, Area of Application, Type of Material Scaffold, End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
AlloSource, BioTissue, Integra Lifesciences Corporation, MiMedx, Organogenesis, Inc., Smith +Nephew, Tissue Regenix, VIVEX Biologics, Alliqua BioMedical, Inc., MISONIX, Inc., Arthrex, Inc., B. Braun Melsungen AG, BARD, A Becton, Dickinson Company, ConMed Corporation, Globus Medical, Inc., Lattice Biologics Ltd., Osiris Therapeutics, Inc., Straumann, Xtant Medical, and Zimmer Biomet Holdings, Inc. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
